Genome Editing VEGFA Prevents Corneal Neovascularization In Vivo

Abstract excerpt

Corneal neovascularization (CNV) is a common clinical finding seen in a range of eye diseases. Current therapeutic approaches to treat corneal angiogenesis, in which vascular endothelial growth factor (VEGF) A plays a central role, can cause a variety of adverse side effects. The technology of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 can edit VEGFA gene to suppress its expression....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Corneal Surgery and Treatments
• Share to CRISPR and Genetic Engineering
• Share to Retinal Development and Disorders